logo
  • SELECT LICENSE :

  • US $4,299.00
  • US $8,599.00

Biosimilars market, By Recombinant Products (Non-Glycosylated Proteins, Glycosylated Proteins, peptides and others) By Application (Oncology, Blood Disorders, Chronic and Auto-immune Disease, infectious diseases and others) opportunities and forecast 2020-2027

  • DLR2233
  • 18 February, 2020
  • Pharma & Healthcare
  • Pages: 120
  • Global
Market Scenario

Biosimilars, also known as biologics are the biological products that are manufactured after the patent expiration of the original products. These are presently available for use in oncology and cancer treatment in the supportive care setting. The focus of these drug developments is expected to switch to agents such as monoclonal antibodies in the coming future. These drugs are highly used in the treatment of cancer and the patent expiration of most of the leading drugs and low cost of these products is the major reason propelling the market growth in the current scenario

Low cost of the products, similar efficacy and potency as that of the original products are some of the major reasons driving the growth of the market. Relatively easier manufacturing and the license to manufacture after the expiration of original products are some of the other reasons adding to the market growth. Complex infrastructure needed for the development of these products and legal procedures for the approval are the major factors restricting the market growth. Other factors limiting the market growth includes high cost for the initial setup and legal procedures that restrict new market entries. Increasing cases of various chronic diseases and the patent expiration of most of the drugs is expected to provide new opportunities to the market in the coming years. Also, the improved affordability due to low cost is expected to increase the patient access to most appropriate therapies.

Segment Analysis

Global biosimilar market has been segmented majorly on the basis of recombinant products and applications. On the basis of recombinant products the market has been segmented as non-glycosylated proteins, glycosylated proteins, peptides and others. Non-glycosylated recombinant proteins are further divided into insulin, HGH, interferon and others. Further on the basis of application, the market has been segmented as oncology, blood disorders, chronic and autoimmune diseases, infectious diseases and others.

Regional Analysis

Geographically, the market has been segmented into four major economies including North America, Europe, Asia-Pacific, and LAMEA. North America consists of US, Canada, and Mexico. Europe comprises of the major countries including UK, Germany, France, Italy, Spain and Rest of Europe. Similarly, Asia Pacific consists of the major countries such as, Japan, China, India, South Korea, Australia and, Rest of Asia Pacific. LAMEA consists of Brazil, Saudi Arabia, UAE, and Rest of LAMEA.

Key Players
  1. Pfizer Inc.
  2. Teva Pharmaceuticals
  3. Sandoz International GmBH
  4. Biocon Ltd
  5. F. Hoffmann-La Roche Ltd.
  6. Celltrion Inc.
  7. Amgen
  8. STADA
  9. Merck and Co.
  10. Biogen

Market Segmentation

By Products
  • Recombinant Non Glycosylated Proteins
    • Insulin
    • Human Growth Hormone (HGH)
    • Interferon
    • Others
  • Recombinant Glycosylate Proteins
  • Recombinant Peptides
  • Others
By Application
  • Oncology
  • Blood Disorders
  • Chronic and Autoimmune Disorders
  • Infectious Diseases
  • Others
By Geography
  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • UAE
    • Rest of LAMEA


1 Biosimilars Market Overview

  • 1.1 Biosimilars Product Overview
  • 1.2 Biosimilars Market Segment by Type
    • 1.2.1 Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)
    • 1.2.2 Glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)
    • 1.2.3 Peptides (Glucagon, Calcitonin)
  • 1.3 Global Biosimilars Market Size by Type
    • 1.3.1 Global Biosimilars Sales and Growth by Type
    • 1.3.2 Global Biosimilars Sales and Market Share by Type
    • 1.3.3 Global Biosimilars Revenue and Market Share by Type
    • 1.3.4 Global Biosimilars Price by Type
  • 1.4 North America Biosimilars by Type
  • 1.5 Europe Biosimilars by Type
  • 1.6 South America Biosimilars by Type
  • 1.7 Middle East and Africa Biosimilars by Type

2 Global Biosimilars Market Competition by Company

  • 2.1 Global Biosimilars Sales and Market Share by Company (2014-2019)
  • 2.2 Global Biosimilars Revenue and Share by Company (2014-2019)
  • 2.3 Global Biosimilars Price by Company (2014-2019)
  • 2.4 Global Top Players Biosimilars Manufacturing Base Distribution, Sales Area, Product Types
  • 2.5 Biosimilars Market Competitive Situation and Trends
    • 2.5.1 Biosimilars Market Concentration Rate
    • 2.5.2 Global Biosimilars Market Share of Top 5 and Top 10 Players
    • 2.5.3 Mergers & Acquisitions, Expansion

3 Biosimilars Company Profiles and Sales Data

  • 3.1 Pfizer
    • 3.1.1 Company Basic Information, Manufacturing Base and Competitors
    • 3.1.2 Biosimilars Product Category, Application and Specification
    • 3.1.3 Pfizer Biosimilars Sales, Revenue, Price and Gross Margin(2014-2019)
    • 3.1.4 Main Business Overview
  • 3.2 Sandoz International GmbH
    • 3.2.1 Company Basic Information, Manufacturing Base and Competitors
    • 3.2.2 Biosimilars Product Category, Application and Specification
    • 3.2.3 Sandoz International GmbH Biosimilars Sales, Revenue, Price and Gross Margin(2014-2019)
    • 3.2.4 Main Business Overview
  • 3.3 Teva Pharmaceuticals Industries
    • 3.3.1 Company Basic Information, Manufacturing Base and Competitors
    • 3.3.2 Biosimilars Product Category, Application and Specification
    • 3.3.3 Teva Pharmaceuticals Industries Biosimilars Sales, Revenue, Price and Gross Margin(2014-2019)
    • 3.3.4 Main Business Overview
  • 3.4 Amgen Inc
    • 3.4.1 Company Basic Information, Manufacturing Base and Competitors
    • 3.4.2 Biosimilars Product Category, Application and Specification
    • 3.4.3 Amgen Inc Biosimilars Sales, Revenue, Price and Gross Margin(2014-2019)
    • 3.4.4 Main Business Overview
  • 3.5 Biocon
    • 3.5.1 Company Basic Information, Manufacturing Base and Competitors
    • 3.5.2 Biosimilars Product Category, Application and Specification
    • 3.5.3 Biocon Biosimilars Sales, Revenue, Price and Gross Margin(2014-2019)
    • 3.5.4 Main Business Overview
  • 3.6 Dr. Reddy’s Laboratories
    • 3.6.1 Company Basic Information, Manufacturing Base and Competitors
    • 3.6.2 Biosimilars Product Category, Application and Specification
    • 3.6.3 Dr. Reddy’s Laboratories Biosimilars Sales, Revenue, Price and Gross Margin(2014-2019)
    • 3.6.4 Main Business Overview
  • 3.7 F. Hoffmann-La Roche
    • 3.7.1 Company Basic Information, Manufacturing Base and Competitors
    • 3.7.2 Biosimilars Product Category, Application and Specification
    • 3.7.3 F. Hoffmann-La Roche Biosimilars Sales, Revenue, Price and Gross Margin(2014-2019)
    • 3.7.4 Main Business Overview
  • 3.8 Celltrion
    • 3.8.1 Company Basic Information, Manufacturing Base and Competitors
    • 3.8.2 Biosimilars Product Category, Application and Specification
    • 3.8.3 Celltrion Biosimilars Sales, Revenue, Price and Gross Margin(2014-2019)
    • 3.8.4 Main Business Overview
  • 3.9 Samsung Bioepis
    • 3.9.1 Company Basic Information, Manufacturing Base and Competitors
    • 3.9.2 Biosimilars Product Category, Application and Specification
    • 3.9.3 Samsung Bioepis Biosimilars Sales, Revenue, Price and Gross Margin(2014-2019)
    • 3.9.4 Main Business Overview

4 Biosimilars Market Status and Outlook by Regions

  • 4.1 Global Biosimilars Market Status and Outlook by Regions
    • 4.1.1 Global Biosimilars Market Size and CAGR by Regions
    • 4.1.2 North America
    • 4.1.3 Europe
    • 4.1.4 Asia-Pacific
    • 4.1.5 South America
    • 4.1.6 Middle East and Africa
  • 4.2 Global Biosimilars Sales and Revenue by Regions
    • 4.2.1 Global Biosimilars Sales Market Share by Regions (2014-2019)
    • 4.2.2 Global Biosimilars Revenue Market Share by Regions (2014-2019)
    • 4.2.3 Global Biosimilars Sales, Revenue, Price and Gross Margin (2014-2019)
  • 4.3 North America Biosimilars Sales, Revenue, Price and Gross Margin
    • 4.3.1 North America Biosimilars Sales by Countries
    • 4.3.2 United States
    • 4.3.3 Canada
    • 4.3.4 Mexico
  • 4.4 Europe Biosimilars Sales, Revenue, Price and Gross Margin
    • 4.4.1 Europe Biosimilars Sales by Countries
    • 4.4.2 Germany
    • 4.4.3 France
    • 4.4.4 UK
    • 4.4.5 Italy
    • 4.4.6 Russia
  • 4.5 Asia-Pacific Biosimilars Sales, Revenue, Price and Gross Margin
    • 4.5.1 Asia-Pacific Biosimilars Sales by Regions
    • 4.5.2 China
    • 4.5.3 Japan
    • 4.5.4 South Korea
    • 4.5.5 India
    • 4.5.6 Australia
    • 4.5.7 Indonesia
    • 4.5.8 Thailand
    • 4.5.9 Malaysia
    • 4.5.10 Philippines
    • 4.5.11 Vietnam
  • 4.6 South America Biosimilars Sales, Revenue, Price and Gross Margin
    • 4.6.1 South America Biosimilars Sales by Countries
    • 4.6.2 Brazil
  • 4.7 Middle East and Africa Biosimilars Sales, Revenue, Price and Gross Margin
    • 4.7.1 Middle East and Africa Biosimilars Sales by Countries
    • 4.7.2 Turkey
    • 4.7.3 GCC Countries
    • 4.7.4 Egypt
    • 4.7.5 South Africa

5 Biosimilars Application

  • 5.1 Biosimilars Segment by Application
    • 5.1.1 Oncology
    • 5.1.2 Blood Disorders
  • 5.2 Global Biosimilars Product Segment by Application
    • 5.2.1 Global Biosimilars Sales by Application
    • 5.2.2 Global Biosimilars Sales and Market Share by Application (2014-2019)
  • 5.3 North America Biosimilars by Application
  • 5.4 Europe Biosimilars by Application
  • 5.5 Asia-Pacific Biosimilars by Application
  • 5.6 South America Biosimilars by Application
  • 5.7 Middle East and Africa Biosimilars by Application

6 Global Biosimilars Market Forecast

  • 6.1 Global Biosimilars Sales, Revenue Forecast (2019-2025)
    • 6.1.1 Global Biosimilars Sales and Growth Rate Forecast (2019-2025)
    • 6.1.2 Global Biosimilars Revenue and Growth Rate Forecast (2019-2025)
  • 6.2 Global Biosimilars Forecast by Regions
    • 6.2.1 North America Biosimilars Sales and Revenue Forecast (2019-2025)
    • 6.2.2 Europe Biosimilars Sales and Revenue Forecast (2019-2025)
    • 6.2.3 Asia-Pacific Biosimilars Sales and Revenue Forecast (2019-2025)
    • 6.2.4 South America Biosimilars Sales and Revenue Forecast (2019-2025)
    • 6.2.5 Middle East and Africa Biosimilars Sales and Revenue Forecast (2019-2025)
  • 6.3 Biosimilars Forecast by Type
    • 6.3.1 Global Biosimilars Sales and Revenue Forecast by Type (2019-2025)
    • 6.3.2 Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon) Growth Forecast
    • 6.3.3 Glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin) Growth Forecast
  • 6.4 Biosimilars Forecast by Application
    • 6.4.1 Global Biosimilars Sales Forecast by Application (2019-2025)
    • 6.4.2 Global Biosimilars Forecast in Oncology
    • 6.4.3 Global Biosimilars Forecast in Blood Disorders

7 Biosimilars Upstream Raw Materials

  • 7.1 Biosimilars Key Raw Materials
    • 7.1.1 Key Raw Materials
    • 7.1.2 Key Raw Materials Price
    • 7.1.3 Raw Materials Key Suppliers
  • 7.2 Manufacturing Cost Structure
    • 7.2.1 Raw Materials
    • 7.2.2 Labor Cost
    • 7.2.3 Manufacturing Expenses
  • 7.3 Biosimilars Industrial Chain Analysis

8 Marketing Strategy Analysis, Distributors

  • 8.1 Sales Channel
  • 8.2 Distributors
  • 8.3 Downstream Customers

9 Research Findings and Conclusion

    10 Appendix

    • 10.1 Methodology/Research Approach
      • 10.1.1 Research Programs/Design
      • 10.1.2 Market Size Estimation
      • 10.1.3 Market Breakdown and Data Triangulation
    • 10.2 Data Source
      • 10.2.1 Secondary Sources
      • 10.2.2 Primary Sources
    • 10.3 Author List

    Report You Might be Interested